Pfizer has been steadily building a franchise around its inflammatory diseases pill, Xeljanz (tofacitinib) over the last few years, and it could add another use after US experts recommended
Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires.
